{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000003","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.198190+00:00","generated_at":"2026-06-06T01:02:05.031871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent","bullets":["Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).","Q4 2023 net loss $90.2M ($1.18/sh); cash and equivalents $566.9M at Dec 31, 2023.","Received 459 new patient start forms for FILSPARI in Q4; total 1,452 PSFs since Feb 2023 approval.","Expects to submit sNDA for full U.S. approval of FILSPARI in IgAN in Q1 2024; CHMP opinion on EU CMA also Q1.","Pivotal Phase 3 HARMONY study of pegtibatinase in HCU enrolling; topline data expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000003","json":"https://secwatch.observer/filing/0001438533-24-000003.json","markdown":"https://secwatch.observer/filing/0001438533-24-000003.md","text":"https://secwatch.observer/filing/0001438533-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/tvtx-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:02:05.031871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e60e5563ce6261b1c231ad9ea83cac02f70e5ba6","claim":"Travere Therapeutics, Inc. reported financial results for the quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On February 15, 2024, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}